# US 2026/0216255 A1 · Strain of collinsella, and pharmaceutical composition thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0216255 A1 - Document ID: US20260216255A1 - Status: Published application - Kind: A1 - Application number: 19/143,614 - Filed: 2024-01-02 - Published: 2026-07-30 - Earliest claimed: 2022-12-30 - Assignees: Moon (Guangzhou) Biotech Co., Ltd. - Applicants: Moon (Guangzhou) Biotech Co., Ltd. - Inventors: YIBO XIAN; ZHENZHEN LIU; BAOJIA HUANG; PING KONG - Web page: https://patentgrep.com/patent/US20260216255A1 ## CPC - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61P 3/06: Antihyperlipidemics - A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) - A61K 38/26: Glucagons - A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies} - A61P 3/04: Anorexiants; Antiobesity agents - A61P 35/00: Antineoplastic agents - C12N 1/20: Bacteria; Culture media therefor - C12N 1/205: Bacterial isolates - A61K 2035/11: {Medicinal preparations comprising living procariotic cells} - A61K 2039/505: {comprising antibodies} - C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS ## Abstract Provided herein are a novel species of Collinsella and a pharmaceutical composition thereof. The Gram-negative Collinsella sp. obtained through screening was named Collinsella sp. MNH 18574. Through routine species identification, it is determined that the bacterium is a new species of the genus Collinsella. Metabolite prediction and experiments in tumor models prove that the bacterium can increase the expression of multiple induced inflammatory factors, reduce the expression of anti-inflammatory factors, and can significantly improve the survival conditions of various tumor mouse models (such as lung cancer, pancreatic cancer, etc.). The bacterium can be used for developing drugs for preventing or treating various cancers. Metabolic experiments such as mouse liver and kidney function experiments and mouse obesity intervention experiments prove that the bacterium can improve and prevent metabolic diseases. ## Claims ### Claim 1 (canceled) ### Claim 2 (canceled) ### Claim at position 3 3: A pharmaceutical composition, for use in prevention and/or treatment of a tumor, diabetes mellitus or obesity disease, comprising at least one of the microbial strain, a fermentation broth, a supernatant of a fermentation broth, an extract from a fermentation broth, or a metabolite of said microbial strain; the microbial strain is selected from the following: (1) the microbial strain is a new species of the genus Collinsella (Collinsella sp.), and is useful for the prevention and/or treatment of tumors; and wherein the nucleotide sequence of 16s rRNA of the microbial strain has a similarity of more than 98.65% to the nucleotide sequence as set forth in SEQ ID No: 1; (2) the microbial strain is a new species of the genus Collinsella (Collinsella sp.), and is useful for the prevention and/or treatment of tumors; and wherein the nucleotide sequence of 16s rRNA of the microbial strain has a similarity of greater than or equal to 98.7%, 99%; 99.3%, 99.5%, 99.8%, 99.9%, or 100% to the nucleotide sequence as set forth in SEQ ID No: 1; (3) the microbial strain comprises Collinsella sp. MNH 18574, which was deposited with the Guangdong Microbial Culture Collection Center with a deposit name of Collinsella sp. MNH 18574 and a deposit number of GDMCC No: 62667; (4) the microbial strain has an average nucleotide identity (ANI) value of at least 81.5% to the Collinsella strain with a deposit number of GDMCC No: 62667; (5) the microbial strain has an average nucleotide identity (ANI) value of at least 81.5% to the Collinsella strain with a deposit number of GDMCC No: 62667; the average nucleotide identity (ANI) value is 82%, 85%, 90%, 92%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%; the composition comprising one or more pharmaceutically acceptable excipient or food-acceptable carriers or excipients, and/or a probiotic. ### Claim 4 (canceled) ### Claim 5 (canceled) ### Claim at position 6 (depends on 3) 6: The composition according to claim 3, wherein the excipient is at least one selected from a carrier, an excipient, a diluent, a lubricant, a wetting agent, an emulsifier, a suspension stabilizer, a preservative, a sweetener, and a flavor. ### Claim 7 (canceled) ### Claim at position 8 (depends on 3) 8: The composition according to claim 3, wherein the composition further comprises an immunosuppressive agent; selected from the following: (1) wherein the immunosuppressive agent comprises at least one of a PD-1 inhibitor, a CTLA-4 inhibitor, or a PD-L1 inhibitor; optionally, (2) the immunosuppressive agent comprises at least one of an anti-PD-1 antibody, an anti-CTLA-4 antibody, or an anti-PD-L1 antibody; wherein the anti-PD-L1 antibody is selected from durvalumab, atezolizumab, or avelumab; the anti-PD-1 antibody is selected from pembrolizumab or nivolumab; the anti-CTLA-4 antibody is selected from ipilimumab or tremelimumab. ### Claim at position 9 (depends on 3) 9: The composition according to claim 3, wherein the composition further comprises at least one of a glucose-lowering agent, a fat-reducing agent, a weight-reducing agent, or a GLP-1 receptor agonist. ### Claim at position 10 (depends on 9) 10: The composition according to claim 9, for use in preventing or treating a tumor, diabetes mellitus, obesity, a liver function disorder, a liver and kidney function disorder, inflammation, a metabolic disorder caused by obesity, a cardiovascular or cerebrovascular disease, hyperlipidemia, or atherosclerosis, and optionally comprises a pharmaceutically or food-acceptable carrier or excipient. ### Claim at position 11 (depends on 10) 11: The composition according to claim 10, wherein the tumor is selected from the following: 1) at least one of a solid tumor, a soft tissue tumor, a hematopoietic tumor, an adenoma, or a metastatic tumor; 2) the tumor is a clinically refractory tumor or a drug-resistant tumor; more preferably, the clinically refractory tumor comprises tumors with a low response to a PD-1 drug; the drug-resistant tumor comprises tumors resistant to a PD-1 drug and/or tumors resistant to a chemical agent, a chemotherapeutic agent, and/or an immunotherapeutic agent; and the clinically refractory tumor or drug-resistant tumor comprises at least one of lung cancer, liver cancer, and pancreatic cancer; 3)_the tumor comprises tumors resistant to an immunotherapeutic agent, such as tumors resistant to an anti-PD-1 antibody, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, and/or a PD-L1 inhibitor; 4) the tumor is selected from one or more of: liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, bile duct cancer, kidney cancer, glioma, liposarcoma, chondrosarcoma, fibrosarcoma, melanoma, cervical cancer, neuroblastoma, lymphoma, leukemia, gastric cancer, hematological malignancy, prostate cancer, small cell lung cancer, squamous cell carcinoma, head and neck tumor, bladder cancer, nasopharyngeal cancer, and multiple myeloma, and still preferably, the tumor is selected from one or more of: melanoma, glioma, head and neck tumor, lung cancer, colorectal cancer, bladder cancer, nasopharyngeal cancer, liver cancer, kidney cancer, pancreatic cancer, lymphoma (preferably cutaneous T-cell lymphoma or peripheral T-cell lymphoma), ovarian cancer, fibrosarcoma, and multiple myeloma. ### Claim at position 12 (depends on 10) 12: The composition according to claim 10, wherein the composition prevents and/or treats a tumor by at least one of the following pathways: (a) inhibiting tumor volume growth; (b) inhibiting tumor weight increase; (c) inhibiting tumor cell growth; (d) improving the tumor response rate to a therapy; (e) improving the therapeutic efficacy of an immunosuppressive agent, e.g., improving the therapeutic efficacy of a PD-1 drug; (f) inhibiting tumor cell metastasis; (g) reducing resistance to a PD-1 drug; (h) inhibiting the tumor by at least one short-chain fatty acid or short-chain fatty acid salt of acetic acid or acetate, propionic acid or propionate, butyric acid or butyrate, valeric acid or valerate in SCFA; (i) inhibiting the tumor by regulating the subject's immune system to exert an immunomodulatory effect; or (j) promoting or activating the subject's immune system (e.g., increasing CD4+ or CD8+ T cell content) to kill the tumor or inhibit tumor growth. ### Claim at position 13 13-17. (canceled) ### Claim at position 14 18: A method of treating tumors or diabetes mellitus or obesity disease, comprising administering to a subject at least one of a microbial strain, a fermentation broth, a supernatant of a fermentation broth, an extract from a fermentation broth, or a metabolite of said microbial strain: the microbial strain is selected from the following: (1) the microbial strain is a new species of the genus Collinsella (Collinsella sp.), and is useful for the prevention and/or treatment of tumors; and wherein the nucleotide sequence of 16s rRNA of the microbial strain has a similarity of more than 98.65% to the nucleotide sequence as set forth in SEQ ID No: 1; (2) the microbial strain is a new species of the genus Collinsella (Collinsella sp.), and is useful for the prevention and/or treatment of tumors; and wherein the nucleotide sequence of 16s rRNA of the microbial strain has a similarity of greater than or equal to 98.7%, 99%; 99.3%, 99.5%, 99.8%, 99.9%, or 100% to the nucleotide sequence as set forth in SEQ ID No: 1; (3) the microbial strain comprises Collinsella sp. MNH 18574, which was deposited with the Guangdong Microbial Culture Collection Center with a deposit name of Collinsella sp. MNH 18574 and a deposit number of GDMCC No: 62667; (4) the microbial strain has an average nucleotide identity (ANI) value of at least 81.5% to the Collinsella strain with a deposit number of GDMCC No: 62667; (5) the microbial strain has an average nucleotide identity (ANI) value of at least 81.5% to the Collinsella strain with a deposit number of GDMCC No: 62667; the average nucleotide identity (ANI) value is 82%, 85%, 90%, 92%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%. ### Claim 19 (canceled) ### Claim at position 16 (depends on 18) 20: The method of treating tumors or diabetes mellitus or obesity disease by administering a composition, wherein the composition comprising at least one of the microbial strain, a fermentation broth, a supernatant of a fermentation broth, an extract from a fermentation broth, or a metabolite of said microbial strain according to claim 18, and one or more pharmaceutically or food-acceptable carriers or excipients, and/or a probiotic. ### Claim at position 17 (depends on 20) 21: The method of treating tumors or diabetes mellitus or obesity disease according to claim 20, wherein the composition further comprises an immunosuppressive agent selected from the following: (1) the immunosuppressive agent comprises at least one of a PD-1 inhibitor, a CTLA-4 inhibitor, or a PD-L1 inhibitor; (2) the immunosuppressive agent comprises at least one of an anti-PD-1 antibody, an anti-CTLA-4 antibody, or an anti-PD-L1 antibody; wherein the anti-PD-L1 antibody is selected from durvalumab, atezolizumab, or avelumab; the anti-PD-1 antibody is selected from pembrolizumab or nivolumab; the anti-CTLA-4 antibody is selected from ipilimumab or tremelimumab. ### Claim at position 18 (depends on 21) 22: The method of treating tumors or diabetes mellitus or obesity disease according to claim 21, wherein the composition further comprises at least one of a glucose-lowering agent, a fat-reducing agent, a weight-reducing agent, or a GLP-1 receptor agonist. ### Claim at position 19 (depends on 22) 23: The method of treating tumors or diabetes mellitus or obesity disease according to claim 22, wherein the composition is a drug product, a health care product, or a food product for preventing or treating tumors, diabetes mellitus, obesity, a liver function disorder, a liver and kidney function disorder, inflammation, a metabolic disorder caused by obesity, a cardiovascular or cerebrovascular disease, hyperlipidemia, or atherosclerosis, and optionally comprises a pharmaceutically or food-acceptable carrier or excipient. ### Claim at position 20 (depends on 23) 24: The method of treating tumors or diabetes mellitus or obesity disease according to claim 23, wherein the tumor is selected from the following: 1) at least one of a solid tumor, a soft tissue tumor, a hematopoietic tumor, an adenoma, or a metastatic tumor; 2) the tumor is a clinically refractory tumor or a drug-resistant tumor; more preferably, the clinically refractory tumor comprises tumors with a low response to a PD-1 drug; the drug-resistant tumor comprises tumors resistant to a PD-1 drug and/or tumors resistant to a chemical agent, a chemotherapeutic agent, and/or an immunotherapeutic agent; and the clinically refractory tumor or drug-resistant tumor comprises at least one of lung cancer, liver cancer, and pancreatic cancer; 3) the tumor comprises tumors resistant to an immunotherapeutic agent, such as tumors resistant to an anti-PD-1 antibody, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, and/or a PD-L1 inhibitor; 4) the tumor is selected from one or more of: liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, bile duct cancer, kidney cancer, glioma, liposarcoma, chondrosarcoma, fibrosarcoma, melanoma, cervical cancer, neuroblastoma, lymphoma, leukemia, gastric cancer, hematological malignancy, prostate cancer, small cell lung cancer, squamous cell carcinoma, head and neck tumor, bladder cancer, nasopharyngeal cancer, and multiple myeloma, and still preferably, the tumor is selected from one or more of: melanoma, glioma, head and neck tumor, lung cancer, colorectal cancer, bladder cancer, nasopharyngeal cancer, liver cancer, kidney cancer, pancreatic cancer, lymphoma (preferably cutaneous T-cell lymphoma or peripheral T-cell lymphoma), ovarian cancer, fibrosarcoma, and multiple myeloma. ### Claim at position 21 (depends on 23) 25: The method of treating tumors or diabetes mellitus or obesity disease according to claim 23, wherein the composition prevents and/or treats tumors by at least one of the following pathways: (a) inhibiting tumor volume growth; (b) inhibiting tumor weight increase; (c) inhibiting tumor cell growth; (d) improving the tumor response rate to a therapy; (e) improving the therapeutic efficacy of an immunosuppressive agent, e.g., improving the therapeutic efficacy of a PD-1 drug; (f) inhibiting tumor cell metastasis; (g) reducing resistance to a PD-1 drug; (h) inhibiting the tumor by at least one short-chain fatty acid or short-chain fatty acid salt of acetic acid or acetate, propionic acid or propionate, butyric acid or butyrate, valeric acid or valerate in SCFA; (i) inhibiting the tumor by regulating the subject's immune system to exert an immunomodulatory effect; or (j) promoting or activating the subject's immune system (e.g., increasing CD4+ or CD8+ T cell content) to kill the tumor or inhibit tumor growth. ### Claim at position 22 (depends on 23) 26: The method of treating tumors or diabetes mellitus or obesity disease according to claim 23, wherein the diabetes mellitus is type II diabetes, insulin resistance syndrome, glucose intolerance, a complication of diabetic nephropathy, diabetic neuropathy, diabetic ophthalmopathy, or diabetic foot. ### Claim at position 23 (depends on 23) 27: The method of treating tumors or diabetes mellitus or obesity disease according to claim 23, wherein the composition is administered orally. ### Claim at position 24 (depends on 10) 28: The composition according to claim 10, wherein the diabetes mellitus is type II diabetes, insulin resistance syndrome, glucose intolerance, a complication of diabetic nephropathy, diabetic neuropathy, diabetic ophthalmopathy, or diabetic foot. ### Claim at position 25 (depends on 3) 29: The composition according to claim 3, wherein the composition further comprises at least one of a glucose-lowering agent, a fat-reducing agent, a weight-reducing agent, or a GLP-1 receptor agonist. ### Claim at position 26 (depends on 9) 30: The composition according to claim 9, wherein the glucose-lowering agent is metformin; the fat-reducing agent or weight-reducing agent is at least one of liraglutide, dulaglutide, or semaglutide. ### Claim at position 27 (depends on 10) 31: The composition according to claim 10, wherein the diabetes mellitus is type II diabetes, insulin resistance syndrome, glucose intolerance, a complication of diabetic nephropathy, diabetic neuropathy, diabetic ophthalmopathy, or diabetic foot.